BioCentury
ARTICLE | Finance

Shire shopping

Shire tipped as both buyer, target in M&A rumors

June 16, 2014 7:00 AM UTC

Given a two-year buying spree by Shire plc (LSE:SHP; NASDAQ:SHPG), it comes as little surprise the company is mentioned in virtually every rumor relating to a biotech takeout in the rare disease and ophthalmology spaces, even if its cash hoard has dwindled as a result of its deal flow.

Since Flemming Ornskov became CEO designate in October 2012, Shire has announced a slew of acquisitions...